Literature DB >> 24054032

Lack of association of hepatic estrogen receptor-alpha expression with histopathological and biochemical findings in chronic hepatitis C.

Gulbanu Erkan1, Guldal Yilmaz, Mustafa Cengiz, Ceyla Konca Degertekin, Gulen Akyol, Seren Ozenirler.   

Abstract

Estrogens exert a protective effect against hepatic steatosis and fibrosis. Loss of estrogen receptor-alpha (ER-α) in the liver is associated with hepatic steatosis and inflammation in animal models. We conducted a study in order to investigate the presence and extent of ER-α expression in HCV infection, and its relationship with histological and biochemical findings. Ninety biopsy-proven chronic hepatitis C (CHC) patients were enrolled in the study. Liver biopsy specimens were immunohistochemically stained for ER-α expression. Nuclear ER-α expression percentage was calculated. ER-α was positive in 69 of the patients (76%). ER-α positive and negative groups were not significantly different in terms of age, gender, necroinflammatory activity, fibrosis, steatosis, serum levels of AST, ALT, ALP, GGT, and bilirubin. ER-α expression percentage was not correlated with fibrosis, steatosis, necroinflammatory activity and biochemical findings. Although estrogens are known to be protective against fibrosis and steatosis in animal models, we did not find any significant correlation between ER-α expression and histopathological and biochemical findings in CHC patients. These findings should be verified in further large scale studies.
Copyright © 2013 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Chronic hepatitis C; Estrogen receptor-alpha

Mesh:

Substances:

Year:  2013        PMID: 24054032     DOI: 10.1016/j.prp.2013.08.006

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  1 in total

1.  Estrogen receptor alpha expression and liver fibrosis in chronic hepatitis C virus genotype 1b: a clinicopathological study.

Authors:  Mustafa Cengiz; Seren Ozenirler; Guldal Yılmaz
Journal:  Hepat Mon       Date:  2014-09-24       Impact factor: 0.660

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.